SCHEMBL5442154

SCHEMBL5442154

Cc1cc(N[C@H]2CC[C@H](N)C2)nc2ccc(F)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CCNT1 O60563 5/20 0.46
CDK9 P50750 4/20 0.46
CDK1 P06493 2/20 0.46
CDK4 P11802 2/20 0.46
CCNA2 P20248 2/20 0.46
CCND1 P24385 2/20 0.46
CCNE1 P24864 2/20 0.46
CDK2 P24941 2/20 0.46
CDK7 P50613 2/20 0.46
CCNH P51946 2/20 0.46
CCNA1 P78396 2/20 0.46
CDK3 Q00526 2/20 0.46
MCHR1 Q99705 8/20 0.44
ALDH1A1 P00352 1/20 0.39
JAK2 O60674 1/20 0.38
ATM Q13315 1/20 0.38
CDK6 Q00534 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5799103 0.83 MCHR1 (0.62) KDM4ELMNASMN1; SMN2MCHR1MAPK6
SCHEMBL5433478 0.83 MCHR1 (0.62) KDM4ELMNASMN1; SMN2MCHR1MAPK6
SCHEMBL5434587 0.83 ATM (0.47) KDM4ELMNASMN1; SMN2MCHR1JAK2
SCHEMBL5433640 0.80 ALDH1A1 (0.56) KDM4ELMNASMN1; SMN2CCNT1CDK9
SCHEMBL5943481 0.78 MCHR1 (0.62) KDM4ELMNASMN1; SMN2MCHR1
SCHEMBL5943477 0.78 KDM4E (0.74) KDM4ELMNASMN1; SMN2MCHR1ALDH1A1
SCHEMBL5433454 0.76 MCHR1 (0.60) MCHR1
SCHEMBL6456703 0.76 KDM4E (0.75) KDM4ELMNASMN1; SMN2CDK9CDK2
SCHEMBL6459301 0.76 KDM4E (0.75) KDM4ELMNASMN1; SMN2CDK9CDK2
Hydrochloric Acid SCHEMBL6928682 0.74 KDM4E (0.73) KDM4ELMNASMN1; SMN2CDK9CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185079-A1 Therapeutic agents I ASTRAZENECA AB (SE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185079-A1 Therapeutic agents I HTT, GRIN2A, GRIN1 KDM4E 2659/4885LMNA 3591/4885SMN1; SMN2 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.